Navigation Links
Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
Date:1/10/2011

(all amounts in millions of dollars) for the full year 2010: Year EndYear EndIncrease12/31/201012/31/2009(Decrease)Testim U.S. Revenue

$190.0$152.025.0%Testim Ex – U.S. & Contract Revenue

3.08.5(64.2%)Total Testim Revenue

$193.0$160.520.3%XIAFLEX U.S. Revenue

$14.1n/an/aXIAFLEX Contract Revenue

4.33.622.1%Total XIAFLEX Revenue

$18.4$3.6416.7%Total Worldwide Revenue

$211.4$164.028.9%Contract Revenues represent amortization of previously received upfront and milestone payments.

2011 XIAFLEX Net Revenue GuidanceFor 2011, Auxilium anticipates that 2011 XIAFLEX net revenues will be in the range of $55.0 to $67.0 million, including approximately $50.0 to 60.0 million in U.S. revenue, and $5.0 to 7.0 million in revenue recognized from royalties and milestones under the Pfizer contract.  

Upcoming Investor PresentationAuxilium reported these numbers in advance of a presentation to investors tomorrow, January 11, 2011 at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, when Auxilium's Chief Executive Officer and President, Armando Anido, will outline the Company's strategic priorities.

Mr. Anido will speak at 4:00 p.m. PT (7:00 p.m. ET) tomorrow, and his remarks will be webcast via a link on the "For Investors" section of www.auxilium.com. Mr. Anido will give an overview of the Auxilium current business strategy, which will focus on the following areas:

  • maximizing the value of Testim and XIAFLEX,
  • delivering on the current pipeline,
  • building out the pipeline in specialty therapeutic areas.

  • A PDF of the presentation slides to be used during the remarks is now available on the "For Investors" section of the Auxilium web site under the "Presentations" tab.  A question and answer session will follow tomorrow's presentation and will also be webcast.  The presentation webcast, the presenta
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
    5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
    6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
    7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
    (Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
    ... K-V Pharmaceutical Company (NYSE:  KVa/KVb) (the "Company") today announced that ... U.S. Healthcare II, L.L.C. (together the "Lenders") that grant Lenders ... Company,s Class A Common Stock, par value $.01 per share ... second warrant to Lenders that grants Lenders the right to ...
    ... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced its unaudited financial results ... ("2Q FY2010"). 2Q FY20 10 ... increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million). ...
    Cached Medicine Technology:K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 2K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 3K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 4K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 5K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 6K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 7K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 8K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 9K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14
    (Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
    (Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
    (Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
    (Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
    (Date:4/17/2014)... 17, 2014 Meaningful long-term survival is possible ... the abdomen when treated with cytoreductive surgery with ... first-of-its-size analysis by physicians at Wake Forest Baptist ... largest reported, single-center experience with cytoreductive surgery and ... and analysis of 20 years, worth of patient ...
    Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
    ... homeless population among New Yorkers are more prone to go ... the population. // Detox centers will be established at some ... on the rise. Rapid HIV testing for women who are ... the Health Department. ,A large number of ...
    ... Copeman Healthcare of Canada has been warned of fines by ... insured health services. Copeman Healthcare intends to establish clinics in ... it will be charging a joining fee of $1,200, and ... ,The medicare law of the state says ...
    ... worst hit by AIDS. But now after bringing in changes in ... the initial sex // and using condoms have greatly reduced the ... ,It was found that among women in the age group of ... was witnessed among men in the age group of 17-29. ...
    ... model has been developed that can predict the occurrence of ... mild or severe can be told five months before it ... emergency measures to be done in advance. ,The ... officials these days. ,The problem is greatest ...
    ... by a House of Lords committee has revealed that 90 ... tested on them. Dangerous drugs like morphine, // thyrozine, the ... the treatment of children even though there was no valid ... ,The report also alleges that some high-risk medications like asthma ...
    ... recruit 50,000 people as a part of a large study called ... between lifestyle and genetics as regards the health of an individual. ... and is one of the largest healthcare projects in the UK. ... of information so that it would be easy to assess who ...
    Cached Medicine News:Health News:Prediction of malaria epidemics possible! 2
    ... Volk's super series ... lenses. Variable retinal ... unprecedented fundus diagnostic ... maximum potential field ...
    Volk indirect lenses. Wide field retinal diagnosis & treatment....
    Volk indirect lenses. High magnification views of the posterior pole....
    ... This contact class is particularly ... lamps which have a smaller ... the reduction prism than the ... fundus / iridocornea. Mirror angle ...
    Medicine Products: